The San Diego-based company said the touch screen, and intuitive menu mimic a smartphone, designed to support increased adherence to therapy. The dual listed $US40.7 billion giant said its proprietary therapy algorithms for AutoSet or APAP (auto-adjusting PAP) delivers breath-by-breath therapy adjustments, and has a ‘Her mode’ – setting tailored to treat the female-specific characteristics of mild to moderate obstructive sleep apnoea.
The AirSense 11 also gives access to patient app myAir and remote monitoring platform for clinicians AirView – which bring overall patient adherence as high as 87 per cent, ResMed said.
The myAir app tracks the amount of time patients spend using CPAP therapy, number of sleep apnoea events per hour, mask leak, and the number of times a mask was removed, providing nightly data on breathing, coaching tips, and support directly to their phone.
AirView provides a secure, cloud-based patient management system for online patient monitoring that enables healthcare professionals to quickly access patient data, share clinical insights with other health professionals, improve care and reduce costs related to patient follow-up.
Earlier in August, chief executive Mick Farrell tipped it would gain between $US300 million to $US350 million ($470 million) in increased sales of sleep disorder devices this year after Netherlands-based Philips announced a €250 million ($394 million) global recall of a flow generator in June.
Morgan Stanley analysts expect ResMed to achieve at least $US350 million in additional sales, boosted by the tailwind of the AirSense 11 launch. This benefit will fall to $US200 million and $US135 million in financial years 2023 and 2024, respectively, the analysts said.
While ResMed is gaining from its rival’s stumble, it faces supply chain constraints that is hampering its ability to take full advantage of the situation.
No gross margin guidance was provided at the recent update when it flagged a 236 basis point decline to 57.3 per cent in the fourth quarter. But margins are likely to remain under pressure this year due to elevated freight costs, component shortage and pricing as well as more lower-margin devices being sold and fewer ventilators.